In our experience, these 2 cases were the 69 th and 93 rd cases. At the early stage in the learning curve of robotic surgery, RALP would have been difficult to perform in both of these cases, ...
TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
PSA clearance after BPE surgery follows a rapid, predictable pattern. Learn how TURP and OSP impact PSA levels and clinical ...
Better continence, erectile function, but data on oncologic outcomes still 2 years away ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
Original Medicare (parts A and B) covers medically necessary prostate surgeries, including treatments for an enlarged prostate and prostate cancer. Medicare covers various prostate procedures, ...
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
We recently reported our initial experience with single-port transvesical enucleation of the prostate (STEP) performed through a solitary suprapubic incision via a single-access port inserted directly ...